A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
Public ClinicalTrials.gov record NCT04178902. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First In Human Study of the MCL-1 Inhibitor, ABBV-467
Study identification
- NCT ID
- NCT04178902
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 8 participants
Conditions and interventions
Conditions
Interventions
- ABBV-467 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 18, 2020
- Primary completion
- Apr 15, 2021
- Completion
- Apr 15, 2021
- Last update posted
- Jul 25, 2021
2020 – 2021
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center - North Campus /ID# 219102 | Tucson | Arizona | 85719-1478 | — |
| City of Hope /ID# 209786 | Duarte | California | 91010 | — |
| Hackensack Univ Med Ctr /ID# 221035 | Hackensack | New Jersey | 07601 | — |
| Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418 | Providence | Rhode Island | 02903-4923 | — |
| Prisma Health Cancer Institute-Faris Road /ID# 219076 | Greenville | South Carolina | 29605-4255 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04178902, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 25, 2021 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04178902 live on ClinicalTrials.gov.